

A U T H O R I N D E X

- Abbatecola**, A. M. 113–118
Agbaje, O. F. 551–560
Ahluwalia, A. 399–401
Ahuja, K. D. K. 355–361
Akahira, J. 709–713
Akatsu, T. 39–44
Al-Attas, O. 467–472
Albarrak, A. I. S. 551–560
Al-Daghri, N. M. 467–472
Alegre, J. 601–607
Alemán, C. 601–607
Al-Ghafra, A. 419–423
Allen, A. R. 677–682
Alméras, N. 89–95
Anchisi, S. 105–111
Andersen, N. H. 59–66
Andersson, S. E. 699–707
André, M. 437–446
Anglés, A. 601–607
Antico, A. 105–111
Aragoncillo, P. 655–662
Armadans, L. 601–607
Arndt, B. 373–382
Arnesen, H. 13–20
Arslan, M. 181–185
Ashton E. L. 355–361
Avella, M. 363–371
Axelrod, F. B. 295–301

Bahr, M. J. 373–382
Bain, S. C. 467–472
Ball, M. J. 355–361
Bär, D. P. R. 29–37
Bartlett, W. A. 467–472
Bashir, O. 323–330
Basu, S. 81–87
Bayraktutan, U. 677–682
Beckmann, M. W. 279–285
Behan, W. M. H. 213–218
Beinder, E. 279–285
Belch, J. J. F. 577–584
Bellard, E. 331–337
Belyaev, N. D. 467–472
Berlanga-Acosta, J. 323–330
Berne, C. 81–87, 715–721
Berstad, P. 13–20

Best, J. D. 569–575
Bidani, A. 21–28
Blann, A. D. 507–512
Blum, S. 437–446
Boden, L. E. 591–599
Boeker, K. H. W. 373–382
Botham, K. M. 363–371
Bouchard, C. 89–95
Boutouyrie, P. 637–644
Bozec, E. 637–644
Brennecke, S. P. 419–423
Breuillé, D. 437–446
Brooks, C. R. 127–140
Brown, C. 295–301
Brown, M. D. 473–482
Brys, M. 295–301
Buffière, C. 437–446
Bulayeva, N. N. 21–28
Bulpitt, C. J. 219–225
Burrell, L. M. 339–345
Büssemaker, E. 513–518
Butler, A. R. 577–584
Butler, T. J. 243–250

Cable, N. T. 663–669
Cachofeiro, V. 655–662
Camaro, C. 315–322
Casley, D. J. 339–345
Catalano, M. 105–111
Cediel, E. 655–662
Cernacek, P. 647–653
Cerretelli, P. 105–111
Chang, C.-C. 287–294
Chang, H. 287–294, 447–456
Chin, B. S. P. 507–512
Cinteza, M. 591–599
Claydon, V. 119–126
Cleland, S. J. 187–194
Cloud, G. C. 219–225
Coakley, J. H. 691–698
Coats, P. 683–689
Cockcroft, J. R. 141–160
Connell, J. M. C. 187–194
Convery, A. 425–430
Cooke, J. 219–225

Cooper, V. L. 119–126
Cordeiro, M. F. 723
Cox, R. 621–628

Dabire, H. 637–644
Daniel, W. G. 45–50
da Nóbrega, A. C. L. 161–165
Darnel, A. D. 709–713
Dean, R. G. 339–345
DeAngelo, J. 629–635
de Boer, E. 51–57
de Dios, I. 203–212
de Faire, U. 615–620
de Haan, A. 585–589
de Jong, P. E. 51–57
de Jong, S. 67–71
de la Mano, A. M. 203–212
de las Heras, N. 655–662
Delles, C. 97–103
de Moraes, A. V. 161–165
Denis, P. 437–446
Denis, R. G. P. 403–408
de Sousa, E. B. 161–165
Després, J.-P. 89–95
de With, M. C. J. 29–37
de Zeeuw, D. 51–57
Díaz, C. 655–662
Diver, M. J. 663–669
Dobešová, Z. 483–489
Dominguez, M. 347–353
Donelan, L. 499–506
Doucet, E. 89–95
Dransfield, I. 273–278
Dupuis, J. 227–234, 647–653
Dupuis, J.-M. 331–337

Ebina, M. 709–713
Edvinsson, L. 699–707
Edvinsson, M.-L. 699–707
Egginton, S. 473–482
Eiskjær, H. 59–66
Ekici, A. 181–185
Ekici, M. 181–185
Elliott, J. 363–371

Elliott, K. J. 663–669
El Yousfi, M. 437–446
Enkhbaatar, P. 621–628, 629–635
Enomoto, M. 431–435
Estadella, D. 403–408
Evans, A. E. 677–682

Fassot, C. 637–644
Fatani, S. 403–408
Fauler, J. 513–518
Ferguson, C. N. 691–698
Ferguson, J. W. 1–8
Fernández de Sevilla, T. 601–607
Ferretti, G. 105–111
Fischer, T. 279–285
Fitzgerald, A. J. 323–330
Fleming, I. 513–518
Flemming, P. 373–382
Fogarty, D. G. 677–682
Fortrat, J.-O. 331–337
Fraser, A. G. 591–599
Frenneaux, M. P. 141–160
Frostegård, J. 615–620
Fugmann, A. 715–721
Furukawa, K.-I. 73–79
Fusch, C. 195–202

Garlichs, C. D. 45–50
Garlick, P. J. 691–698
Gelman, J. S. 499–506
Georgiades, E. 213–218
Gerrits, K. 585–589
Gibbs, C. R. 507–512
Godsland, I. F. 531–532
Gommans, I. 585–589
Goodlad, R. A. 323–330
Gould, G. W. 187–194
Goulter, A. B. 363–371
Graham, R. J. 499–506
Grella, R. 113–118
Gross, P. 513–518
Gude, N. M. 419–423
Gulli, G. 119–126

S U B J E C T I N D E X

- A**cinar cell
 cholecystokinin, oxygen free radical 203–212
- Acute myocardial infarction
 leucocyte, tumour necrosis factor- α (TNF- α) 39–44
- Adiponectin
 diet, obesity 403–408
- Adrenomedullin
 fetal membrane, placenta 419–423
- Aging
 heart failure, inflammation 699–707
- Albumin synthesis
 parenteral nutrition, sepsis 691–698
- Alkalosis
 macrophage, calcium homoeostasis 21–28
- Allograft
 muscle function, pre-storage perfusion 29–37
- Androgen receptor
 branching morphogenesis, fetal lung 709–713
- Angiogenesis
 skeletal muscle, vascular endothelial growth factor (VEGF) 473–482
- Angiopoietin
 myocardial ischaemia/reperfusion, Tie receptor 287–294
- Angiotensin-converting enzyme (ACE)
 atherosclerosis, inflammatory marker 655–662
 nephrosis, proteinuria 51–57
 neutral endopeptidase, vasopectidase inhibitor 339–345
- Angiotensinogen
 intima-media thickness, polymorphism 637–644
- Anti-inflammatory cytokine
 chronic heart failure, interleukin-10 (IL-10) 45–50
- Antioxidant
 epidemiology, microalbuminuria 569–575
 oxidative injury, periodontal disease 167–172
- Aorta
 vasodilation, endothelial cell 73–79
- Apolipoprotein
 cholesteryl ester transfer protein (CETP), high-density lipoprotein (HDL) 467–472
- Apoptosis
 fetuin, phagocytosis 267–268, 273–278
- Arrhythmogenicity
 long QT syndrome (LQTS), QT dispersion 671–676
- Arterial pressure
 central aortic pressure, non-invasive method 219–225
- Asymmetrical dimethylarginine (ADMA)
 menopause, cardiovascular disease 9–10, 67–71
- Atherosclerosis
 fibrinolytic system, inhibition 655–662
 fish oil supplementation, vascular cell-adhesion molecule (VCAM) 13–20
 hypertension, oxidized low-density lipoprotein (OxLDL) 615–620
 inflammatory marker, angiotensin-converting enzyme (ACE) 655–662
- Autonomic nervous system
 blood volume, respiratory-related arterial pressure 491–497
 haemodynamic response, hyperinsulinaemia 315–322
- B**aroreflex
 syncope, orthostatic intolerance 119–126
- Bayesian analysis
 insulin sensitivity, minimal model 531–532, 551–560
- Bile secretion
 obstructive cholestasis, transcytosis 347–353
- β -Blocker selection
 chronic heart failure, oxidative stress 507–512
- Blood pressure
 nitric oxide (NO), N^G -nitro-L-arginine methyl ester (L-NAME) 483–489
- Blood pressure variability
 essential hypertension, renovascular hypertension 545–547, 609–614
 heart rate variability, hyperinsulinaemia 315–322
- Blood volume
 respiratory-related arterial pressure, autonomic nervous system 491–497
- Bradykinin
 cytochrome P450, vasodilation 399–401, 513–518
- Branching morphogenesis
 fetal lung, androgen receptor 709–713
- Breathlessness
 exercise testing, respiratory control 243–250
- Bronchoconstriction
 dyspnoea, pulmonary disease 181–185
- Burn
 ketorolac, nitric oxide (NO) 549–550, 621–628
- C**alcium channel
 vitisin C, vasodilation 73–79
- Calcium homoeostasis
 alkalosis, macrophage 21–28
- Cardiac function
 ghrelin, growth hormone-releasing peptide 431–435
 mental stress, pyridostigmine 161–165
- Cardiovascular disease
 oestrogen replacement therapy, nitric oxide (NO) 9–10, 67–71

- Central aortic pressure
non-invasive method, arterial
pressure 219–225
- Central nervous system
chronic fatigue syndrome, exercise
213–218
- Chlamydia pneumoniae*
subclinical atherosclerosis, twins
303–313
- Cholecystokinin
oxygen free radical, acinar cell
203–212
- Cholesteryl ester transfer protein
(CETP)
high-density lipoprotein (HDL),
apolipoprotein 467–472
- Chronic fatigue syndrome
central nervous system, exercise
213–218
- Chronic heart failure
interleukin-10 (IL-10), anti-
inflammatory cytokine
45–50
oxidative stress, β -blocker
selection 507–512
- Chylomicron remnant-like particle
endothelial function, nitric oxide
(NO) 363–371
- Circadian rhythm
renal excretion, RNA catabolite
195–202
- Cirrhosis
endothelin, peptide clearance
227–234
hepatitis C, matrix
metalloproteinase 373–382
- Colitis
inflammatory bowel disease,
protein metabolism
437–446
- Connexin 43
haemopoiesis, repopulation
561–568
- Coronary artery
endothelial cell, chylomicron
remnant-like particle 363–371
- C-peptide
endothelial function, diabetes
mellitus 113–118
- Critical limb ischaemia
microcirculation, regional blood
flow 683–689
- Crypt fission
intestinal cell proliferation,
epidermal growth factor (EGF)
323–330
- Cyclo-oxygenase (COX)
ketorolac, nitric oxide (NO)
549–550, 621–628
- Cytochrome P450
vasodilation, bradykinin 399–401,
513–518
- Cytokine
chronic heart failure, inflammation
45–50
fibrinolysis system, pleural effusion
541–543, 601–607
- D**
Diabetes mellitus
C-peptide, endothelial function
113–118
left ventricle, echocardiography
59–66
- Diabetic pregnancy
macrosomia, polyunsaturated fatty
acid 519–529
- Diastolic function
echocardiography, mitral annulus
395–397, 499–506
- Diet
endothelium-dependent
vasodilation, fatty acid 81–87
obesity, adiponectin 403–408
- Dietary intervention
lipid oxidation, low-density
lipoprotein (LDL)
355–361
- Dietary sodium restriction
insulin resistance, renin–angiotensin
system 187–194
- Doppler imaging
diabetes mellitus, ejection fraction
59–66
- Dyspnoea
pulmonary disease,
bronchoconstriction 181–185
- E**
Echocardiography
diabetes mellitus, left ventricle
59–66
mitral annulus, diastolic function
395–397, 499–506
- Endothelial function
diabetes mellitus, C-peptide
113–118
inflammation, vascular reactivity
699–707
nitric oxide (NO), chylomicron
remnant-like particle
363–371
- Endothelin
hypertrophy, pulmonary
hypertension 647–653
peptide clearance, cirrhosis
227–234
- Endothelium
statin, vascular protection 251–266
- Endothelium-dependent vasodilation
fatty acid, diet 81–87
hypercholesterolaemia, oxidative
stress 11–12, 97–103
- Energetics
exercise, peripheral arterial disease
105–111
- Epidemiology
microalbuminuria, antioxidant
569–575
- Epidermal growth factor (EGF)
multiple intestinal neoplasia, polyp
formation 323–330
- Essential hypertension
renovascular hypertension, blood
pressure variability 545–547,
609–614
- Evolution
MHC class I, natural killer cell
127–140
- Exercise
oxidative stress, uric acid 425–430
peripheral arterial disease,
energetics 105–111
weight loss, obesity 89–95
- Exercise testing
respiratory control, breathlessness
243–250
- F**
Factor V Leiden
HELLP syndrome, intrauterine
growth restriction 269–271,
279–285
- Familial dysautonomia
plethysmography, vessel
hyperperfusion 295–301
- Fatty acid
diet, endothelium-dependent
vasodilation 81–87
endothelial dysfunction,
atherosclerosis 13–20
- Fetal lung
androgen receptor, branching
morphogenesis 709–713
- Fetal membrane
placenta, adrenomedullin 419–423
- Fetuin
phagocytosis, apoptosis 267–268,
273–278

- Fibrinolysis system
pleural effusion, cytokines 541–543, 601–607
- Fish oil supplementation
atherosclerosis, vascular
cell-adhesion molecule (VCAM) 13–20
- Ghrelin**
growth hormone-releasing peptide, cardiac function 431–435
- Glucocorticoid receptor
sepsis, skeletal muscle 383–391
- Glutamine
growth hormone, sepsis 691–698
- Growth hormone-releasing peptide
cardiac function, ghrelin 431–435
- Haemodynamic response**
hyperinsulinaemia, autonomic nervous system 315–322
vasovagal syncope, venous congestion 331–337
- Haemodynamics
insulin, lipid 645–646, 715–721
- Haemopoiesis
repopulation, connexin 43 561–568
- Heart failure
inflammation, aging 699–707
natriuretic peptide, vascular resistance 141–160
- HELLP syndrome
intrauterine growth restriction, factor V Leiden 269–271, 279–285
- Hepatitis C
matrix metalloproteinase, cirrhosis 373–382
- High-density lipoprotein (HDL)
apolipoprotein, cholesteryl ester transfer protein (CETP) 467–472
- Homocysteine
oxidative stress, redox balance 173–180
- Human leucocyte antigen-DR (HLA-DR)
organ failure, pancreatitis 409–417
- 3-Hydroxy 3-methylglutaryl-CoA (HMG-CoA)
inflammation, statin 251–266
- Hypercholesterolaemia
oxidative stress, endothelium-dependent vasodilation 11–12, 97–103
- Hyperinsulinaemia
autonomic nervous system, haemodynamic response 315–322
- Hypertension
mitogen-activated protein kinase (MAPK), sodium/magnesium exchanger 235–242
oxidized low-density lipoprotein (OxLDL), atherosclerosis 615–620
- Hypertrophy
pulmonary hypertension, endothelin 647–653
- Hypotension
interleukin-2 (IL-2), nitric oxide (NO) scavenger 629–635
- Hypoxia-inducible factor (HIF)
mechanical stretch, smooth muscle cell 393–394, 447–456
- Immunohistochemistry**
5 α -reductase, fetal lung 709–713
- Inflammation
aging, heart failure 699–707
- Inflammatory bowel disease
protein metabolism, colitis 437–446
- Inflammatory marker
angiotensin-converting enzyme (ACE), atherosclerosis 655–662
- Inhibitor
sulphaphenazole, cytochrome P450 399–401, 513–518
- Insulin
lipid, haemodynamics 645–646, 715–721
lipoprotein lipase, postprandial lipaemia 457–466
- Insulin resistance
renin–angiotensin system, dietary sodium restriction 187–194
- Insulin sensitivity
minimal model, Bayesian analysis 531–532, 551–560
- Interleukin-2 (IL-2)
nitric oxide (NO) scavenger, hypotension 629–635
- Interleukin-10 (IL-10)
anti-inflammatory cytokine, chronic heart failure 45–50
- Intima-media thickness
polymorphism, angiotensinogen 637–644
- Intrauterine growth restriction
factor V Leiden, HELLP syndrome 269–271, 279–285
- Ischaemia
receptor, vascular endothelial growth factor (VEGF) 473–482
- Ischaemic heart disease
NADP(H) oxidase, polymorphism 677–682
- Ketorolac**
nitric oxide (NO), burn 549–550, 621–628
- Left ventricle**
echocardiography, diabetes mellitus 59–66
- Leptin
obesity, caloric restriction 89–95
- Leucocyte
tumour necrosis factor- α (TNF- α), acute myocardial infarction 39–44
- Lipid
haemodynamics, insulin 645–646, 715–721
- Lipid oxidation
low-density lipoprotein (LDL), dietary intervention 355–361
- Lipoprotein lipase
postprandial lipaemia, insulin 457–466
- Liver cirrhosis
vasopressin receptor, water excretion 1–8
- Long QT syndrome (LQTS)
QT dispersion, arrhythmogenicity 671–676
- Low-density lipoprotein (LDL)
dietary intervention, lipid oxidation 355–361
- Macrophage**
calcium homeostasis, alkalosis 21–28
- Macrosomia
polyunsaturated fatty acid, diabetic pregnancy 519–529
- Matrix metalloproteinase
cirrhosis, hepatitis C 373–382
- Mechanical stretch
smooth muscle cell, hypoxia-inducible factor (HIF) 393–394, 447–456
- Menstrual cycle
muscle strength, oestradiol 663–669
- Mental stress
pyridostigmine, cardiac function 161–165

- MHC class I
natural killer cell, evolution 127–140
- Microalbuminuria
antioxidant, epidemiology 569–575
- Microcirculation
regional blood flow, critical limb ischaemia 683–689
- Minimal model
Bayesian analysis, insulin sensitivity 531–532, 551–560
- Mitogen-activated protein kinase (MAPK)
sodium/magnesium exchanger, hypertension 235–242
- Mitral annulus
diastolic function, echocardiography 395–397, 499–506
- Multiple intestinal neoplasia
polyp formation, epidermal growth factor (EGF) 323–330
- Muscle function
pre-storage perfusion, allograft 29–37
- Muscle strength
oestradiol, menstrual cycle 663–669
- Muscle weakness
nemaline myopathy, neuromuscular disease 585–589
- Myocardial ischaemia/reperfusion
Tie receptor, angiotensin 287–294
- NADP(H)** oxidase
polymorphism, ischaemic heart disease 677–682
- Natriuretic peptide
vascular resistance, heart failure 141–160
- Natural killer cell
evolution, MHC class I 127–140
- Nemaline myopathy
neuromuscular disease, muscle weakness 585–589
- Nephrosis
proteinuria, angiotensin-converting enzyme (ACE) 51–57
- Neuromuscular disease
muscle weakness, nemaline myopathy 585–589
- Neutral endopeptidase
vasopeptidase inhibitor, angiotensin-converting enzyme (ACE) 339–345
- Neutrophil
 α_2 -HS glycoprotein, fetuin 267–268, 273–278
- Nitric oxide (NO)
burn, ketorolac 549–550, 621–628
cardiovascular disease, oestrogen replacement therapy 9–10, 67–71
chylomicron remnant-like particle, endothelial function 363–371
 N^G -nitro-L-arginine methyl ester (L-NAME), blood pressure 483–489
- Nitric oxide (NO) donor
S-nitrosated thiosugar, vasodilation 533–535, 577–584
- Nitric oxide (NO) scavenger
hypotension, interleukin-2 (IL-2) 629–635
- N^G -Nitro-L-arginine methyl ester (L-NAME)
blood pressure, nitric oxide (NO) 483–489
- S-Nitrosated thiosugar
vasodilation, nitric oxide (NO) donor 533–535, 577–584
- Non-invasive method
arterial pressure, central aortic pressure 219–225
- Obesity**
adiponectin, diet 403–408
exercise, weight loss 89–95
- Obstructive cholestasis
transcytosis, bile secretion 347–353
- Oestradiol
menstrual cycle, muscle strength 663–669
- Oestrogen replacement therapy
nitric oxide (NO), cardiovascular disease 9–10, 67–71
- Organ failure
pancreatitis, human leucocyte antigen-DR (HLA-DR) 409–417
- Orthostatic intolerance
baroreflex, syncope 119–126
- Oxidative injury
periodontal disease, antioxidant 167–172
- Oxidative stress
 β -blocker selection, chronic heart failure 507–512
endothelium-dependent vasodilation, hypercholesterolaemia 11–12, 97–103
redox balance, homocysteine 173–180
uric acid, exercise 425–430
- Oxidized low-density lipoprotein (OxLDL)
atherosclerosis, hypertension 615–620
- Oxygen free radical
acinar cell, cholecystokinin 203–212
- p22phox** polymorphism
nitric oxide (NO), endothelium-dependent vasodilation 11–12, 97–103
- Pancreatitis
human leucocyte antigen-DR (HLA-DR), organ failure 409–417
oxidative stress, cholecystokinin 203–212
- Parenteral nutrition
sepsis, albumin synthesis 691–698
- Peptide clearance
cirrhosis, endothelin 227–234
- Periodontal disease
antioxidant, oxidative injury 167–172
- Peripheral arterial disease
exercise, energetics 105–111
- Phagocytosis
apoptosis, fetuin, 267–268, 273–278
- Placenta
adrenomedullin, fetal membrane 419–423
- Plethysmography
vessel hyperperfusion, familial dysautonomia 295–301
- Pleural effusion
cytokines, fibrinolysis system 541–543, 601–607
- Polymorphism
angiotensinogen, intima-media thickness 637–644
ischaemic heart disease, NADP(H) oxidase 677–682
- Polyp formation
epidermal growth factor (EGF), multiple intestinal neoplasia 323–330
- Polyunsaturated fatty acid
diabetic pregnancy, macrosomia 519–529
- Postprandial dysfunction
atherosclerosis, diet 81–87
- Postprandial lipaemia
insulin, lipoprotein lipase 457–466
- Pre-storage perfusion
allograft, muscle function 29–37

- Protein metabolism
colitis, inflammatory bowel disease 437–446
- Prothrombin mutation
pregnancy complication, intrauterine growth restriction 269–271, 279–285
- Proteinuria
angiotensin-converting enzyme (ACE), nephrosis 51–57
- Pulmonary disease
bronchoconstriction, dyspnoea 181–185
- Pulmonary hypertension
endothelin, hypertrophy 647–653
- Pyridostigmine
cardiac function, mental stress 161–165
- QT** dispersion
arrhythmogenicity, long QT syndrome (LQTS) 671–676
- Redox** balance
homocysteine, oxidative stress 173–180
- Regional blood flow
critical limb ischaemia, microcirculation 683–689
- Renal excretion
RNA catabolite, circadian rhythm 195–202
- Renal protein catabolism
angiotensin-converting enzyme (ACE), rat model 51–57
- Renin–angiotensin system
dietary sodium restriction, insulin resistance 187–194
- Renovascular hypertension
blood pressure variability, essential hypertension 545–547, 609–614
- Repopulation
connexin 43, haemopoiesis 561–568
- Respiratory control
breathlessness, exercise testing 243–250
- Respiratory-related arterial pressure
autonomic nervous system, blood volume 491–497
- RNA catabolite
circadian rhythm, renal excretion 195–202
- Sepsis**
albumin synthesis, parenteral nutrition 691–698
skeletal muscle, glucocorticoid receptor 383–391
- Skeletal muscle
glucocorticoid receptor, sepsis 383–391
vascular endothelial growth factor (VEGF), angiogenesis 473–482
- Smooth muscle cell
hypoxia-inducible factor (HIF), mechanical stretch 393–394, 447–456
- Sodium/magnesium exchanger
hypertension, mitogen-activated protein kinase (MAPK) 235–242
- Statin
vascular protection, endothelium 251–266
- Stress echocardiography
Type II diabetes, ventricular function 537–540, 591–599
- Subclinical atherosclerosis
twins, *Chlamydia pneumoniae* 303–313
- Syncope
orthostatic intolerance, baroreflex 119–126
- Tie** receptor
angiopoietin, myocardial ischaemia/reperfusion 287–294
- Transcytosis
bile secretion, obstructive cholestasis 347–353
- Tumour necrosis factor- α (TNF- α)
acute myocardial infarction, leucocyte 39–44
- Twins
Chlamydia pneumoniae, subclinical atherosclerosis 303–313
- Type II diabetes
ventricular function, stress echocardiography 537–540, 591–599
- Uric acid**, exercise
oxidative stress 425–430
- Vascular cell-adhesion molecule (VCAM)**
fish oil supplementation, atherosclerosis 13–20
- Vascular endothelial growth factor (VEGF)
angiogenesis, skeletal muscle 473–482
- Vascular protection
endothelium, statin 251–266
- Vascular resistance
heart failure, natriuretic peptide 141–160
- Vasodilation
bradykinin, cytochrome P450 399–401, 513–518
calcium channel, vitisin C 73–79
nitric oxide (NO) donor, S-nitrosated thiosugar 577–584, 533–535
- Vasopeptidase inhibitor
angiotensin-converting enzyme (ACE), neutral endopeptidase 339–345
- Vasopressin receptor
liver cirrhosis, water excretion 1–8
- Vasovagal syncope
venous congestion, haemodynamic response 331–337
- Vasovagal syndrome
baroreflex, heart rate variability 119–126
- Venous congestion
haemodynamic response, vasovagal syncope 331–337
- Ventricular function
stress echocardiography, Type II diabetes 537–540, 591–599
- Vessel hyperperfusion
familial dysautonomia, plethysmography 295–301
- Vitisin C
vasodilation, calcium channel 73–79
- Water** excretion
vasopressin receptor, liver cirrhosis 1–8
- Weight loss
obesity, exercise 89–95

- H**
Haapiainen, R. 409–417
Haas, M. 51–57
Haberkorn, C. I. 373–382
Hadjicharalambous, M. 213–218
Hainsworth, R. 119–126
Hak-Lemmers, H. L. M. 173–180
Hammar, N. 303–313
Hart, S. P. 273–278
Hartikainen, J. 315–322, 609–614
Hawkins, H. 621–628
Hayashi, M. 269–271
Hayes, P. C. 1–8
Heming, T. A. 21–28
Hernández, G. 655–662
Herndon, D. 621–628
Hilgers, K. F. 97–103
Hilz, M. J. 295–301
Hinds, C. J. 691–698
Hiramori, K. 39–44
Hjerkinn, E. M. 13–20
Holst, B. 591–599
Hosoda, H. 431–435
Hovorka, R. 551–560
Huang, F.-Y. 491–497
Huang, Y. 97–103
Hubner, R. A. 339–345
Hudlicka, O. 473–482
Huopio, H. 315–322
- H**
Ikäheimo, R. 609–614
Imbeault, P. 89–95
Ino, H. 671–676
Iob, G. 105–111
Isik, F. 549–550
Iteginli, A. 181–185
- J**
Jackson, K. G. 457–466
Jansson, S.-E. 409–417
Jartti, L. 303–313
Järvisalo, M. J. 303–313
Jasmin, J.-F. 647–653
Jenkins, A. J. 569–575
Jersmann, H. P. A. 273–278
Jeunemaitre, X. 637–644
John, S. 97–103
Johnston, C. I. 339–345
Jones, A. F. 467–472
- K**
Kalpaklioglu, F. 181–185
Kaneda, T. 671–676
Kaneko, C. 709–713
Kangawa, K. 431–435
Kanmatsuse, K. 431–435
- K**
Kaprio, J. 303–313
Kara, T. 181–185
Karadeniz, Y. 181–185
Karlström, B. 81–87
Kautiainen, H. 409–417
Kempainen, E. 409–417
Khakoo, S. I. 127–140
Khan, F. 577–584
Khan, N. A. 519–529
Kilduff, L. P. 213–218
Kimura, Y. 709–713
King, R. G. 419–423
Knapper-Francis, J. M. E. 457–466
Kodzuka, G. 73–79
Kojima, M. 431–435
Koll, M. 691–698
Kon, M. 29–37
Konno, T. 671–676
Kooner, J. 219–225
Koskenvuo, M. 303–313
Kroese, A. B. A. 29–37
Kuan, P. 287–294, 447–456
Kubota, E. 339–345
Kumar, S. 467–472
Kuneš, J. 483–489
Kuo, T. B. J. 491–497
Kuo, Y. L. 491–497
Kurdowska, A. K. 541–543
Kurtipek, E. 181–185
Kylänpää-Bäck, M.-L. 409–417
- L**
Laakso, M. 315–322
Lacolley, P. 637–644
Lahera, V. 655–662
Lai, H. Y. 491–497
Laitinen, T. 315–322, 609–614
Langley-Evans, S. C. 167–172
Lässig, G. 513–518
Laurent, S. 637–644
Lee, S. 629–635
Lee, Y. 491–497
Lefthériotis, G. 331–337
Lehner, C. 45–50
Lemne, C. 615–620
Lichtinghagen, R. 373–382
Lind, L. 81–87, 715–721
Lip, G. Y. H. 507–512
Lord, J. M. 267–268
Loures, D. L. 161–165
Lunn, D. J. 551–560
Luzio, S. D. 551–560
- M**
Mabuchi, H. 671–676
Mabuchi, T. 671–676
Macias, R. I. R. 347–353
Mackie, E. E. 213–218
Mädler, C. F. 591–599
Mammen, J. M. V. 383–391
Manns, M. P. 373–382
Manso, M. A. 203–212
Manz, F. 195–202
Manzella, D. 113–118
Marconi, C. 105–111
Marin, J. J. G. 347–353
Marniemi, J. 303–313
Marthol, H. 295–301
Marwick, T. H. 537–540
Mason, J. C. 251–266
Mauriège, P. 89–95
Maxwell, S. R. J. 425–430
McGlinchey, P. G. 677–682
McGrath, B. P. 9–10
McKeown, P. P. 677–682
Meijer, D. K. F. 51–57
Mentula, P. 409–417
Merzouk, H. 519–529
Mesquita, E. T. 161–165
Michels, D. 373–382
Milkiewicz, M. 473–482
Millgård, J. 715–721
Mishra, V. 425–430
Mitchell, J. A. 393–394
Mogensen, C. E. 59–66
Monasterio, J. 601–607
Monte, M. J. 347–353
Moolenaar, F. 51–57
Morgan, L. M. 457–466
Morton, I. J. 187–194
Mosoni, L. 437–446
Motomura, S. 73–79
Mottram, P. M. 499–506
Munroe, P. B. 11–12
Murakami, K. 621–628, 629–635
Murphy, G. 677–682
Mussalo, H. 609–614
- N**
Naderali, E. K. 403–408
Nagaya, N. 431–435
Nagueh, S. F. 395–397
Nakagawa, E. 431–435
Nakamura, M. 39–44
Neele, S. J. M. 67–71
Netelenbos, J. C. 67–71
Newby, D. E. 1–8
Newton, D. J. 577–584
Nicolaides, E. 591–599
Niskanen, L. 315–322
- N**
Niwa, M. 73–79
Nukiwa, T. 709–713
- O**
Obled, C. 437–446
O'Dea, K. 569–575
Oe, K. 671–676
Oehmer, S. 97–103
Okumura, H. 431–435
O'Leary, M. J. 691–698
Ono, F. 431–435
Oshima, Y. 73–79
Oubiña, N. 655–662
Owens, D. R. 551–560
Oya, H. 431–435
- P**
Palmer, T. 187–194
Paolisso, G. 113–118
Papet, I. 437–446
Parati, G. 545–547
Passauer, J. 513–518
Patel, A. 467–472
Patterson, C. C. 677–682
Pearson, R. J. 577–584
Pecháňová, O. 483–489
Pedersen, J. I. 13–20
Peinetti, F. 105–111
Perry, C. G. 187–194
Peters, W. H. M. 173–180
Petrie, J. R. 187–194
Peverill, R. E. 499–506
Pickavance, L. C. 403–408
Pistrosch, F. 513–518
Pitsiladis, Y. P. 213–218
Playford, R. J. 323–330
Poulsen, P. L. 59–66
Poulsen, S. H. 59–66
Preedy, V. R. 691–698
Privalle, C. 629–635
Puolakkainen, P. 409–417
- R**
Ragno, E. 113–118
Raijmakers, M. T. M. 173–180
Raitakari, O. T. 303–313
Rajkumar, C. 219–225
Reed, J. W. 243–250
Rees, A. E. 591–599
Reilly, T. 663–669
Repo, H. 409–417
Rocha, M. 403–408
Roes, E. M. 173–180
Rönnemaa, T. 303–313
Rosendaal, M. 561–568
Rowley, K. 569–575
Rudloff, S. 195–202
Ruiz, E. 601–607

- Saikku, P. 303–313
Salsbury, J. 621–628
Salt, I. P. 187–194
Sant'Anna, I. D. 161–165
Sanz-Rosa, D. 655–662
Sarabi, D. M. 81–87
Sarabi, M. 715–721
Sasano, H. 709–713
Sato, M. 39–44
Scandale, G. 105–111
Schilders, G. W. 173–180
Schlembach, D. 279–285
Schmalstieg, F. C. 629–635
Schmeider, R. E. 97–103
Schmitt, M. 141–160
Schneider, M. P. 97–103
Schöch, G. 195–202
Schwab, A. J. 227–234
Sculley, D. V. 167–172
Segura, R. M. 601–607
Seljeflot, I. 13–20
Seya, K. 73–79
Shenkin, A. 425–430
Shimizu, M. 671–676
Shimoda, K. 621–628,
629–635
Shyu, K.-G. 287–294,
447–456
- Smard, A. 227–234
Spence, M. S. 677–682
Steegeers, E. A. P. 173–180
Steer, P. 81–87
Stehouwer, C. D. A. 67–71
Steinburg, H. O. 645–646
Stemper, B. 295–301
Stone, M. 561–568
St-Pierre, S. 89–95
Stumpf, C. 45–50
Su, Q. 569–575
Subhan, M. M. F. 243–250
Sun, X. 383–391
Suzuki, T. 709–713
- T**akala, A. 409–417
Taniguchi, S. 73–79
Teede, H. J. 9–10
Teerlink, T. 67–71
Terai, H. 671–676
Therapondos, G. 1–8
Thulin, T. 615–620
Tian, X. 383–391
Toledo, M. 347–353
Topp, H. 195–202
Touyz, R. M. 235–242
Traber, D. L. 621–628,
629–635
- Traber, L. D. 621–628,
629–635
Tran Duc, A. T. 227–234
Tremblay, A. 89–95
Tropeano, A.-I. 637–644
Tweddel, A. C. 591–599
- U**chiyama, K. 671–676
Uematsu, M. 431–435
Unverzagt, S. 195–202
Uruñuela, A. 203–212
- v**an der Heijden, E. P. A. B.
29–37
van Engelen, B. 585–589
Vanninen, E. 609–614
Varela, E. 601–607
van Tits, L. J. H. 173–180
Vauhkonen, I. 315–322
Vazquez, D. J. 347–353
Veierød, M. B. 13–20
Verhaeg, J. 473–482
Vessby, B. 81–87
Victor, J. 331–337
Villanueva, G. R. 347–353
Villeneuve, L. 227–234
Vinereanu, D. 591–599
- W**ang, B.-W. 287–294,
447–456
Ward, S. A. 213–218
Waring, W. S. 425–430
Warner, T. D. 393–394
Watts, G. F. 537–540
Webb, D. H. 457–466
Webb, D. J. 425–430
Wehmeier, M. 373–382
Weller, R. 533–535
Welsch, G. 295–301
Werker, P. M. N. 29–37
Williams, C. M. 457–466
Williams, G. 403–408
Wilson, J. 213–218
Witztum, J. L. 615–620
Wu, R. 615–620
Wunsiedler, U. 279–285
- Y**amaguchi, M. 671–676
Yang, C. C. H. 491–497
Yao, G. 235–242
Yilmaz, A. 45–50
Yilmaz, S. 181–185
- Z**ampelas, A. 457–466
Zicha, J. 483–489
Zingsem, J. 279–285